Nutriband Inc. and AVERSA Technology: A Comprehensive FAQ

What is AVERSA technology?

AVERSA technology is Nutriband’s innovation designed to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, by incorporating aversive agents to prevent abuse, diversion, misuse, and accidental exposure, while keeping these drugs accessible to patients who need them.

How does AVERSA technology work?

AVERSA technology can be incorporated into any transdermal patch, including aversive agents that deter abuse without compromising the drug’s efficacy for legitimate medical use.

What patents protect AVERSA technology?

AVERSA technology is protected by a broad intellectual property portfolio with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China.

What recent financial support has Nutriband received for AVERSA technology?

In April 2024, Nutriband closed an $8.4 million financing round to support the commercial development of AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch.

Who is Nutriband’s partner in bringing AVERSA Fentanyl to market?

In February 2025, Nutriband formalized a long-term exclusive partnership with Kindeva Drug Delivery to support AVERSA Fentanyl’s pathway to market.

Where can I find more information about Nutriband and AVERSA technology?

More information about Nutriband and AVERSA technology can be found on their newsroom at https://ibn.fm/NTRB and through BioMedWire’s coverage at https://www.biomedwire.com/nutriband-inc-nasdaq-ntrb-is-one-to-watch-2/.

Why is AVERSA technology significant?

AVERSA technology is significant because it addresses the critical need for abuse-deterrent formulations of potent opioids like fentanyl, potentially reducing abuse and accidental exposure while ensuring these medications remain available for patients with legitimate needs.

What is the potential impact of AVERSA technology on the pharmaceutical industry?

AVERSA technology has the potential to set a new standard for the safety of transdermal drug delivery, particularly for opioids, by combining abuse deterrence with patient accessibility, supported by a robust intellectual property framework.